公开(公告)号：US20230414490A1

公开(公告)日：2023-12-28

申请号：US18244446

申请日：2023-09-11

Applicant: Wyeth, LLC

Inventor： Syed M. Shah ,  Christian Ofslager ,  Mahdi B. Fawzi ,  Nataliya Bazhina

IPC: A61K9/00 ,  A61K47/18 ,  A61K31/485 ,  A61K47/02

CPC classification number: A61K9/0019 ,  A61K47/183 ,  A61K31/485 ,  A61K47/02

Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

公开(公告)号：US20220023407A1

公开(公告)日：2022-01-27

申请号：US17494235

申请日：2021-10-05

Applicant: Wyeth LLC

Inventor： George Rainer Siber ,  Peter R. Paradiso ,  Jill Hackell ,  Stephen Paul Lockhart ,  William P. Hausdorff

IPC: A61K39/09 ,  A61K39/385 ,  A61K39/02

Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

公开(公告)号：USRE48863E1

公开(公告)日：2021-12-28

申请号：US16388011

申请日：2019-04-18

Applicant: WYETH LLC

Inventor： Annaliesa Sybil Anderson ,  Maninder K. Sidhu ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC: A61K39/08 ,  C07K14/00 ,  C07K14/33 ,  C07K16/12 ,  C12N9/10 ,  C12N9/99 ,  C12N15/74

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：USRE48862E1

公开(公告)日：2021-12-28

申请号：US16387999

申请日：2019-04-18

Applicant: WYETH LLC

Inventor： Maninder K. Sidhu ,  Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Narender K. Kalyan ,  Justin Keith Moran ,  Mark E. Ruppen ,  Michael James Flint

IPC: A61K39/08 ,  C07K14/00 ,  C07K14/33 ,  C07K16/12 ,  C12N9/10 ,  C12N9/99 ,  C12N15/74

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US20200093914A1

公开(公告)日：2020-03-26

申请号：US16598661

申请日：2019-10-10

Applicant: Wyeth LLC

Inventor： Annaliesa Sybil Anderson ,  Kathrin Ute Jansen ,  Mark Edward Ruppen ,  Justin Keith Moran ,  Susan Kay Hoiseth

IPC: A61K39/095 ,  C07K14/22

Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide, from serogroup B Neisseria meningitides, and methods related thereto.

公开(公告)号：US20190388537A1

公开(公告)日：2019-12-26

申请号：US16528680

申请日：2019-08-01

Applicant: Wyeth LLC

Inventor： William P. Hausdorff ,  George Rainer Siber ,  Peter R. Paradiso

IPC: A61K39/385 ,  A61K47/64 ,  A61K39/09 ,  A61K39/39

Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

公开(公告)号：US20190117645A1

公开(公告)日：2019-04-25

申请号：US16219159

申请日：2018-12-13

Applicant: Wyeth, LLC

Inventor： Syed M. Shah ,  Christopher Richard Diorio ,  Eric C. Ehrnsperger ,  Xu Meng ,  Kadum A. Al Shareffi ,  Jonathan Marc Cohen

IPC: A61K31/485 ,  A61K9/20 ,  C07D489/08 ,  A61K47/20 ,  A61K47/12 ,  A61K9/28 ,  A61K9/00

CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/28 ,  A61K47/12 ,  A61K47/20 ,  C07D489/08

Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

公开(公告)号：US20180265578A1

公开(公告)日：2018-09-20

申请号：US15844526

申请日：2017-12-16

Applicant: Wyeth LLC

Inventor： Edward Roland LaVallie ,  Lisa Anne Collins-Racie ,  Christopher John Corcoran ,  Lioudmila Gennadievna Tchistiakova ,  John Adam Nowak ,  Riyez Karim ,  Xiang-Yang Tan ,  Kimberly Ann Marquette ,  Geertruida Machteld Veldman

IPC: C07K16/22 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  H05K999/00

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

公开(公告)号：US09981045B2

公开(公告)日：2018-05-29

申请号：US14695582

申请日：2015-04-24

Applicant: Wyeth LLC

Inventor： A. Krishna Prasad

IPC: A61K39/385 ,  A61K47/48 ,  A61K39/09 ,  A61K39/00

CPC classification number: A61K47/646 ,  A61K39/092 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70

Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.

公开(公告)号：US09902771B2

公开(公告)日：2018-02-27

申请号：US14971536

申请日：2015-12-16

Applicant: WYETH LLC

Inventor： Erwin R. Boghaert ,  Nitin K. Damle ,  Philip Ross Hamann ,  Kiran Khandke ,  Arthur Kunz ,  Kimberly A. Marquette ,  Lioudmila Tchistiakova ,  Davinder Gill ,  Sreekumar R. Kodangattil

IPC: C07K16/28 ,  C07K16/30 ,  A61K51/10 ,  C07K14/82 ,  C07K16/32 ,  A61K47/68 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K14/82 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.